Genetic polymorphism of CCND1 G870A and esophageal cancer susceptibility: A meta-analysis

He,Wenwu; Zeng,Yanbei; Long,Jianxiong; Zhou,Qiuxi; Hu,Yanling; Chen,Mingwu

doi:10.3892/br.2012.50

Genetic polymorphism of CCND1 G870A and esophageal cancer susceptibility: A meta-analysis

Authors:
- Wenwu He
- Yanbei Zeng
- Jianxiong Long
- Qiuxi Zhou
- Yanling Hu
- Mingwu Chen
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, P.R. China, Clinical Medicine Major, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, P.R. China, School of Public Health, Guangxi Medical University, Nanning, Guangxi, P.R. China, Department of Cardiology, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, P.R. China, Guangxi Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China
Published online on: December 20, 2012 https://doi.org/10.3892/br.2012.50
Pages: 303-307

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between the polymorphism of cyclin D1 (CCND1) and esophageal carcinogenicity has been widely examined, however, it remains controversial. To evaluate the importance of CCND1 G870A polymorphism with regard to the risk of esophageal cancer, a meta-analysis was carried out that reviewed the available literature in order to clarify the controversies. This meta-analysis included 1,154 cases and 1,678 controls for CCND1 G870A polymorphism from seven published case-control studies. The odds ratio (OR) and 95% confidence interval (CI) were calculated using the Stata software version 11.1. The results were pooled using a dominant model to appropriately reflect a biological model of the genetic effect. No significant association was observed in the Caucasian (OR=1.64; 95% CI, 0.84-3.20) or the Asian populations (OR=1.30; 95% CI, 0.65-2.62), while no significant association was found in esophageal squamous cell carcinoma (ESCC) (OR=1.74; 95% CI, 0.79-3.81) or esophageal adenocarcinoma (EADC) (OR=1.18; 95% CI, 0.77-1.81). However, the comparison of A vs. G in CCND1 G870A showed significant differential susceptibility to esophageal cancer (OR=1.26; 95% CI, 1.00-1.59). These findings suggested that the CCND1 G870A polymorphism has no association with esophageal cancer risk in ethnicity and histology, respectively. Further studies are required to assess these associations in greater detail.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3	Corley DA and Buffler PA: Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 30:1415–1425. 2001. View Article : Google Scholar : PubMed/NCBI
4	Hiyama T, Tanaka S, Shima H, Kose K, Kitadai Y, Ito M, Sumii M, Yoshihara M, Shimamoto F, Haruma K and Chayama K: Somatic mutation of mitochondrial DNA in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Mol Med. 12:169–174. 2003.PubMed/NCBI
5	Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Ther. 1:226–231. 2002. View Article : Google Scholar : PubMed/NCBI
6	Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 11:6075–6086. 2005. View Article : Google Scholar : PubMed/NCBI
7	Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI
8	Knudsen KE, Diehl JA, Haiman CA and Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 25:1620–1628. 2006. View Article : Google Scholar : PubMed/NCBI
9	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
10	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
11	Bagos PG and Nikolopoulos GK: A method for meta-analysis of case-control genetic association studies using logistic regression. Stat Appl Genet Mol Biol. 6:Article17. 2007.PubMed/NCBI
12	Li H, Ha TC and Tai BC: XRCC1 gene polymorphisms and breast cancer risk in different populations: a meta-analysis. Breast. 18:183–191. 2009. View Article : Google Scholar : PubMed/NCBI
13	Yu C, Lu W, Tan W, Xing D, Liang G, Miao X and Lin D: Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 12:1762003.PubMed/NCBI
14	Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G, Wu M, Wei L, He M, Zhang L and Wang S: Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer. 105:281–284. 2003. View Article : Google Scholar : PubMed/NCBI
15	Casson AG, Zheng Z, Evans SC, Geldenhuys L, van Zanten SV, Veugelers PJ, Porter GA and Guernsey DL: Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 104:730–739. 2005. View Article : Google Scholar : PubMed/NCBI
16	Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE and Sarbia M: Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 131:803–808. 2005. View Article : Google Scholar : PubMed/NCBI
17	Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC and Mittal B: Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 31:225–232. 2007. View Article : Google Scholar : PubMed/NCBI
18	Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, et al: p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus. 23:36–39. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hussain S, M Y, Thakur N, Salam I, Singh N, Mir MM, Bhat MA, Siddiqi MA, Das BC and Bharadwaj M: Association of cyclin D1 gene polymorphisms with risk of esophageal squamous cell carcinoma in Kashmir Valley: a high risk area. Mol Carcinog. 50:487–498. 2011. View Article : Google Scholar : PubMed/NCBI
20	Chen B, Cao L, Yang P, Zhou Y and Wu XT: Cyclin D1 (CCND1) G870A gene polymorphism is an ethnicity-dependent risk factor for digestive tract cancers: a meta-analysis comprising 20,271 subjects. Cancer Epidemiol. 36:106–115. 2012. View Article : Google Scholar : PubMed/NCBI
21	Higgins JP: Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 37:1158–1160. 2008. View Article : Google Scholar : PubMed/NCBI
22	Groenwold RH, Rovers MM, Lubsen J and van der Heijden GJ: Subgroup effects despite homogeneous heterogeneity test results. BMC Med Res Methodol. 10:432010. View Article : Google Scholar : PubMed/NCBI